{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:30:57Z","timestamp":1789086657589,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pemigatinib demonstrated efficacy in fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA) in the FIGHT-202 trial. However, limited real-world evidence exists on treatment patterns and outcomes in this setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patient characteristics, treatment patterns, and outcomes of US adults who received pemigatinib for unresectable, locally advanced or metastatic CCA were collected via retrospective physician-abstracted chart review. Results were summarized using descriptive statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 120 patients (49.2% male; 55.0% White; 19.2% Hispanic; median age at initial pemigatinib prescription, 64.5 years) were collected from 18 physicians\/practices. At the time of prescribing, 90.0% of patients had metastatic disease. FGFR2 testing was completed for 92.5% of patients; of those, all but one (result unknown) tested positive, and 95.5% were tested using next-generation sequencing. Pemigatinib was prescribed as second- and third-line therapy among 94.2% and 5.8% of patients, respectively. The most common starting dosage was 13.5\u00a0mg daily for 14 days of 21-day cycles (87.5% of patients). Among 60 patients (50.0% of the full cohort) who discontinued pemigatinib during the 6.5-month median study follow-up period, 68.3% discontinued due to disease progression. The median real-world progression-free survival (rwPFS) from the date of pemigatinib initiation was 7.4 months (95% CI: 6.4-8.6), and the real-world overall response rate (rwORR) was 59.2% (95% CI: 50.0%-68.4%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study complements the FIGHT-202 clinical trial by assessing the use of pemigatinib among a diverse population of patients with CCA under real-world conditions. Findings support the clinical benefit of pemigatinib demonstrated in FIGHT-202.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae204","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:16:26Z","timestamp":1724368586000},"source":"Crossref","is-referenced-by-count":10,"title":["Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-3755","authenticated-orcid":false,"given":"Kim","family":"Saverno","sequence":"first","affiliation":[{"name":"Incyte Corporation , Wilmington, DE ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M","family":"Zimmerman Savill","sequence":"additional","affiliation":[{"name":"Cardinal Health, Real-World Evidence and Insights , Dublin, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherrishe","family":"Brown-Bickerstaff","sequence":"additional","affiliation":[{"name":"Cardinal Health, Real-World Evidence and Insights , Dublin, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angele","family":"Kotomale","sequence":"additional","affiliation":[{"name":"Cardinal Health, Real-World Evidence and Insights , Dublin, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Cardinal Health, Real-World Evidence and Insights , Dublin, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Blecker","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-844X","authenticated-orcid":false,"given":"Richard","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center , Tampa, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"2","key":"2025031509022552000_CIT0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025031509022552000_CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"issue":"14","key":"2025031509022552000_CIT0003","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.12998\/wjcc.v7.i14.1732","article-title":"Diagnostic-therapeutic management of bile duct cancer","volume":"7","author":"Huguet","year":"2019","journal-title":"World J Clin Cases"},{"key":"2025031509022552000_CIT0004","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025031509022552000_CIT0005","author":"American Cancer Society","year":"2023"},{"key":"2025031509022552000_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1477-3163.151940","article-title":"Cancer review: cholangiocarcinoma","volume":"14","author":"Ghouri","year":"2015","journal-title":"J Carcinogen"},{"issue":"6","key":"2025031509022552000_CIT0007","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"Kirstein","year":"2016","journal-title":"Visceral Med"},{"issue":"10","key":"2025031509022552000_CIT0008","doi-asserted-by":"crossref","first-page":"e0186643","DOI":"10.1371\/journal.pone.0186643","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare","volume":"12","author":"Petrick","year":"2017","journal-title":"PLoS One"},{"key":"2025031509022552000_CIT0009","doi-asserted-by":"crossref","first-page":"1758835920953293","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: What\u2019s now and what\u2019s next","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"2025031509022552000_CIT0010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"issue":"15_suppl","key":"2025031509022552000_CIT0011","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2021.39.15_suppl.4089","article-title":"Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion\/rearrangement or wild-type (WT) FGFR2","volume":"39","author":"Shroff","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025031509022552000_CIT0012","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3390\/cancers14112641","article-title":"Timeline of FDA-approved targeted therapy for cholangiocarcinoma","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025031509022552000_CIT0013","author":"Pemazyre\u00ae (pemigatinib) tablets. Full Prescribing Information","year":"2023"},{"issue":"suppl 4","key":"2025031509022552000_CIT0014","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2022.04.443","article-title":"O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"2025031509022552000_CIT0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025031509022552000_CIT0016","author":"QED Therapeutics, Inc","year":"2021"},{"key":"2025031509022552000_CIT0017","author":"Taiho Oncology, Inc","year":"2022"},{"key":"2025031509022552000_CIT0018","author":"FDA News","year":"2022"},{"issue":"10","key":"2025031509022552000_CIT0019","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"2025031509022552000_CIT0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jso.25632","article-title":"Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: what is driving disparities in receipt of treatment","volume":"120","author":"Lee","year":"2019","journal-title":"J Surg Oncol."},{"key":"2025031509022552000_CIT0021","first-page":"1","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Apurva","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"15_suppl","key":"2025031509022552000_CIT0022","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2021.39.15_suppl.4089","article-title":"Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion\/rearrangement or wild-type (WT) FGFR2","volume":"39","author":"Shroff","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025031509022552000_CIT0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2214\/ajr.181.3.1810819","article-title":"Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings","volume":"181","author":"Lim","year":"2003","journal-title":"Am J Roentgenol"},{"issue":"2","key":"2025031509022552000_CIT0024","doi-asserted-by":"crossref","first-page":"e2036741","DOI":"10.1001\/jamanetworkopen.2020.36741","article-title":"Comparison of solid tumor treatment response observed in clinical practice with response reported in clinical trials","volume":"4","author":"Feinberg","year":"2021","journal-title":"JAMA Network Open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae204\/58894151\/oyae204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae204\/58894151\/oyae204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:02:44Z","timestamp":1742029364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae204\/7739122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae204","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,21]]},"article-number":"oyae204"}}